The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
30-Nov-17
$NA
Target:
MorphoSys AG
Acquiror:
I-Mab
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
02-Oct-17
$NA
Target:
Mãe Terra Produtos Naturais Ltda.
Acquiror:
The Unilever Group
Advised Mãe Terra Produtos Naturais Ltda., Brazil’s leading Natural & Organic food products company, on its sale to The Unilever Group
18-Jul-17
$NA
Target:
Radiogroup Participações S.A.
Acquiror:
Grupo Oncoclínicas
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
11-May-17
$245 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
22-Feb-17
$533 million
Target:
Lion’s stake in Warrnambool Cheese and Butter Factory Company
Acquiror:
Saputo Inc.
Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer
27-Jan-17
$4.6 billion
Target:
Booker Group plc
Acquiror:
Tesco plc
Advised Tesco plc, the UK’s leading retailer, on its merger with Booker Group plc, the UK’s leading food wholesaler, to create the UK’s leading food business
22-Dec-16
$290 million
Target:
Subsidiaries and affiliates of Empresas Indumotora S.A.
Acquiror:
Inchcape PLC
Advised Inchcape PLC, a global leader in automotive retail and distribution, on the acquisition of a multi-country scale distribution business in Chile, Peru, Colombia, and Argentina for $290m (approximately £234m)
06-Dec-16
$1.8 billion
Target:
Host Europe Group
Acquiror:
GoDaddy
Advised GoDaddy, the largest domain name registrar worldwide and a leading web hosting provider, on its acquisition of Host Europe Group, the largest privately owned web services provider in Europe
14-Nov-16
$748 million
Target:
Peacock Foods
Acquiror:
Greencore Group plc
Advised Greencore Group plc, a leading international manufacturer of convenience foods based in Ireland, on the proposed acquisition of Peacock Foods, a manufacturing partner for consumer packaged goods companies in the US.
14-Nov-16
$NA
Target:
Lion’s Australian Premium Wine Business – Fine Wine Partners
Acquiror:
Accolade Wines
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
17-Jun-16
$310 million
Target:
Dobbies Garden Centres
Acquiror:
Investor group led by Midlothian Capital Partners and Hattington Capital
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
10-Jun-16
$NA
Target:
Giraffe restaurants
Acquiror:
Boparan Private Office
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of the Giraffe casual dining restaurant chain to the Boparan Private Office, the private investment vehicle of the British businessman Ranjit Boparan
16-May-16
$874 million
Target:
Equinix Data Center Assets
Acquiror:
Digital Realty Trust
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
14-Apr-16
$NA
Target:
Frieze Events Ltd. / Frieze Publishing Ltd.
Acquiror:
WME | IMG Global
Advised Frieze, the premier art events and media company, on its strategic investment and partnership with WME IMG Global
07-Apr-16
$105 million
Target:
Wireless Infrastructure Group
Acquiror:
3i Infrastructure plc
Advised 3i Infrastructure plc, a leading UK listed investor in infrastructure businesses and assets, on its acquisition of a 36% economic interest in Wireless Infrastructure Group, the UK’s 2nd largest independent telecommunications tower company
22-Dec-15
$NA
Target:
Hortifruti
Acquiror:
Partners Group
Advised Hortifruti, Brazil's number one premium retailer of healthy food, on the sale of a significant minority stake to Partners Group, a global private markets investment manager
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
24-Apr-15
$575 million
Target:
Scholastic Corporation’s Educational Technology and Services business
Acquiror:
Houghton Mifflin Harcourt Company
Advised Scholastic Corporation, a children’s publishing and education company, on the sale of its Educational Technology and Services business to Houghton Mifflin Harcourt Company, an educational and trade publisher